Opus Genetics Files 8-K: Reg FD & Financials
Ticker: IRD · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1228627
Sentiment: neutral
Topics: regulation-fd, financials, corporate-actions
TL;DR
Opus Genetics filed an 8-K on 6/23/25 for Reg FD and financials. Formerly Ocuphire/Rexahn.
AI Summary
On June 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Durham, NC.
Why It Matters
This filing provides important updates on Opus Genetics' regulatory compliance and financial status, which are crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, primarily containing disclosures and financial information without significant new operational or financial events.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- June 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 8 Davis Drive Durham, NC 27713 (address) — Principal executive offices
- Ocuphire Pharma, Inc. (company) — Former name
- Rexahn Pharmaceuticals, Inc. (company) — Former name
FAQ
What is the primary purpose of this 8-K filing by Opus Genetics, Inc.?
The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 23, 2025.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive office address for Opus Genetics, Inc. is 8 Davis Drive, Suite 220, Durham, NC 27713.
What were some of the former names of Opus Genetics, Inc.?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
In which state is Opus Genetics, Inc. incorporated?
Opus Genetics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Opus Genetics, Inc. (IRD).